-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in the world, with more than 500,000 HCC cases diagnosed each year worldwide .
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in the world, with more than 500,000 HCC cases diagnosed each year worldwide .
Researchers conducted a retrospective cohort study of CHB patients who had received NA treatment in Hong Kong's electronic medical data repository between 2000 and 2018.
The results of the study showed that among 35,111 CHB patients receiving NA treatment, the average age was 53.
In NA-treated CHB patients, long-term use of aspirin is continuously dependent on the risk of HCC, without significantly increasing the risk of gastrointestinal adverse reactions.
In NA-treated CHB patients, long-term use of aspirin is continuously dependent on the risk of HCC, without significantly increasing the risk of gastrointestinal adverse reactions.
Original source:
Hui, Vicki Wing-Ki BSc.
lww.
com/ctg/Fulltext/2021/03000/Aspirin_Reduces_the_Incidence_of_Hepatocellular.
9.
aspx" target="_blank" rel="noopener">Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Leave a message here
